EGFR and non-small cell lung carcinoma: Subsequently, patients with stage IIIB or stage IV NSCLC and a common EGFR mutation were enrolled in LUX-Lung 7, which compared the effectiveness and safety of afatinib and gefitinib (in exon 19 deletion or Leu858Arg).